Remove Pharma Remove Pharmaceutical manufacturing Remove White Paper
article thumbnail

Using big data to stabilise pharma supply chains in an age of disruption

Pharmaceutical Technology

In an age of disruption, technology is key to enabling pharmaceutical manufacturers monitor, track and control shipments and their processes. Pharmaceutical firms are changing the way they do business; the future winners will be highly automated and digitalised.

Pharma 52
article thumbnail

‘Right shoring’ API production in Europe

Pharmaceutical Technology

In light of the Covid-19 pandemic, the war in Ukraine, and the Russian gas supply issue, several countries have called for onshoring, also referred to as reshoring; the bringing back of pharma production to locations within national borders to mitigate costs, supply issues, and concerns regarding bilateral relations.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

What a mild recession could mean for small biotechs in 2023

Pharmaceutical Technology

Pierre Socha, partner at Amadeus Capital Partners, London, UK, predicts that larger pharmaceutical companies may have similar interests. Most pharmas will buy biotech companies or smaller pharma groups for the quality of their clinical assets and the drugs on their developments,” he says.

article thumbnail

Higher throughput integrity testing: Defining a modern CCIT system for the demands of serial production

Pharmaceutical Technology

Container Closure Integrity Testing (CCIT) is used to evaluate the ability of a pharmaceutical’s primary packaging to protect the sterility of its contents. On a regular basis, pharmaceutical manufacturers are performing CCIT during commercial production to ensure that packaging processes are operating as they should.

article thumbnail

The rising importance of containment in small molecule drug development

Pharmaceutical Technology

Despite the current emphasis on biologic medicines, small molecule drugs still dominate the pharmaceutical manufacturing world. Within the small molecule landscape, several trends are shaping the industry’s future, one of the most notable being the rise of high-potency active pharmaceutical ingredients (HPAPIs).